Pfizer Inc. reported first quarter sales that beat estimates as demand for older blockbusters helped to offset a decline in revenues from Covid products.

Despite the continued decline of Pfizer's COVID-19 products, shares stayed stable on Tuesday morning after the New York pharma reported a first quarter beat, which was led by Eliquis and Ibrance.

Pfizer is looking to newer products and acquisitions to offset a declining Covid business.

Pfizer (PFE) stock gained 0.5% premarket after Q1 EPS of $0.75 topped forecasts. Eliquis drove revenue strength as company maintains 2026 guidance.

Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.

PFE has been testing $26 since February but has breached another key level Pfizer Inc (NYSE:PFE) stock is down 1.1% to trade at $26.03 at last check. PFE is reversing premarket lead despite the pharmaceutical giant reporting adjusted first-quarter earnings of 75 cents per share on $14.

Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets with lower revenues. The big US drugmaker pointed to another drop in quarterly revenues tied to Covid-19 products, as well as $4.4 ...

After reporting record revenue a few years ago, Pfizer has faced tougher times in recent quarters. Challenges include a decline in demand for coronavirus products and patent expirations on the horizon. 10 stocks we like better than Pfizer › A few years ...

Pfizer has a higher-yielding dividend, but it may not be safe. AbbVie has the better path to growth in 2026. But when you look at their finances, AbbVie is the clear winner. Here are three reasons why I prefer AbbVie stock right now.

Pfizer signaled Tuesday it expects a challenging 2026 as it invests in new products to offset declines in Covid-19 revenues while limiting shareholder payouts. Shares of the big drugmaker fell sharply after it projected a dip in full-year adjusted profits ...